Drugs /

pioglitazone

Back to Drugs List

Overview

NCI Definition [1]:
An orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity. Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation.

Clinical Trials

View Clinical Trials for pioglitazone

Pioglitazone has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating pioglitazone, 1 is phase 1/phase 2 (1 open).

ABL1 D276G, ABL1 E255K, and ABL1 E255V are the most frequent biomarker inclusion criteria for pioglitazone clinical trials.

Chronic myeloid leukemia is the most common disease being investigated in pioglitazone clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Pioglitazone
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating pioglitazone and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
pioglitazona, (+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione, pioglitazone, pioglitazone, pioglitazonum, pioglitazone (product), pioglitazone [chemical/ingredient], pioglitazone (substance), 5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione
Drug Target(s) [2]:
PPARG
NCIT ID [1]:
C71633
SNOMED ID [1]:
F-61D2F

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.